ReviewVascular medicine (London, England)2020
COVID-19-associated coagulopathy: An exploration of mechanisms.
Review in Vascular medicine (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 5 syntheses or guidelines pooled it, 284 citations in OpenAlex.
- Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews.European heart journal. Quality of care & clinical outcomes · 2021Pooled it
- Ischemic gastrointestinal complications of COVID-19: a systematic review on imaging presentation.Clinical imaging · 2021Pooled it
- Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Pooled it
- Prevalence of Venous Thromboembolism in Critically Ill Patients With Coronavirus Disease 2019: A Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.European journal of clinical investigation · 2022Trial
- Gender Characteristics of the Novel Coronavirus Infection (COVID-19) in Middle-Aged Adults.Sovremennye tekhnologii v meditsine · 2021Trial
- D-Dimer in Viral Respiratory Infections: Established Evidence in COVID-19 and Emerging Evidence in Other Respiratory Viruses.International journal of molecular sciences · 2026Review
- Thrombophilic Changes and Hematological Complications in Asthmatic Patients with COVID-19: A Systematic Review.Diseases (Basel, Switzerland) · 2025Review
- Incidentally Diagnosed Asymptomatic COVID-19 Does Not Increase Total Complication Risk in Total Joint Arthroplasty.Arthroplasty today · 2025Article
- Management of COVID-19 associated coagulopathy in critically ill patients and the risk of acquired von willebrand syndrome.Scientific reports · 2025Article
- Immunopathological syndromes: state of the art.Frontiers in medicine · 2025Review
- Complex evaluation of coagulation, fibrinolysis, and inflammatory cytokines in SARS-CoV-2 infected pregnant women: a prospective, case-control study.Frontiers in immunology · 2025Observational
- Impacts of COVID-19 on hemostasis: coagulation abnormalities and management perspectives.Annals of medicine and surgery (2012) · 2024Review
- Bleeding and thrombotic events and intensity of heparin therapy in the two first waves of COVID-19.Internal and emergency medicine · 2024Article
- Arterial stiffness in adults with Long COVID in sub-Saharan Africa.Physiological reports · 2024Observational
- Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions.International journal of molecular sciences · 2024Review
- Cq values as an indicator for COVID-19 outcomes: A study of the correlation between laboratory parameters.Immunity, inflammation and disease · 2024Article
- Special Issue "COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies".International journal of molecular sciences · 2024Article
- An early warning indicator of mortality risk in patients with COVID-19: the neutrophil extracellular traps/neutrophilic segmented granulocyte ratio.Frontiers in immunology · 2024Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
An ongoing global pandemic of viral pneumonia (coronavirus disease [COVID-19]), due to the virus SARS-CoV-2, has infected millions of people and remains a threat to many more. Most critically ill patients have respiratory failure and there is an international effort to understand mechanisms and predictors of disease severity. Coagulopathy, characterized by elevations in D-dimer and fibrin(ogen) degradation products (FDPs), is associated with critical illness and mortality in patients with COVID-19. Furthermore, increasing reports of microvascular and macrovascular thrombi suggest that hemostatic imbalances may contribute to the pathophysiology of SARS-CoV-2 infection. We review the laboratory and clinical findings of patients with COVID-19-associated coagulopathy, and prior studies of hemostasis in other viral infections and acute respiratory distress syndrome. We hypothesize that an imbalance between coagulation and inflammation may result in a hypercoagulable state. Although thrombosis initiated by the innate immune system is hypothesized to limit SARS-CoV-2 dissemination, aberrant activation of this system can cause endothelial injury resulting in loss of thromboprotective mechanisms, excess thrombin generation, and dysregulation of fibrinolysis and thrombosis. The role various components including neutrophils, neutrophil extracellular traps, activated platelets, microparticles, clotting factors, inflammatory cytokines, and complement play in this process remains an area of active investigation and ongoing clinical trials target these different pathways in COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.